Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Genentech is the lead sponsor of 37 current clinical trials in our USA, UK, China, India and EU (CTIS) registers. 17 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Atezolizumab, Giredestrant and Inavolisib. The most-studied condition is Breast Cancer.

Company profile on this site (news, sites, medicines, approvals): Genentech (US) →

ClinicalTrials.gov trials by status

Recruiting1749%
Active, closed1851%

Trials by phase

Phase 11646%
Phase 2926%
Phase 4411%
Phase 1/226%
Phase 326%
Observational26%

Clinical trials sponsored by Genentech

35 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04910568 · Multiple Myeloma Drugs: Cevostamab, Daratumumab, Dexamethasone	Phase 1	Recruiting	2021-07	UK, USA
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) NCT04302025 · Non-small Cell Lung Cancer Drugs: Alectinib, Atezolizumab, Cobimetinib	Phase 2	Recruiting	2020-11	USA
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) NCT06979336 · ClinicalTrials.gov ↗ · Ulcerative Colitis	Phase 2	Recruiting	2025-09	UK, USA, India, China
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events NCT07448038 · Atherosclerosis	Phase 2	Recruiting	2026-06	USA
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease NCT06603246 · Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease	Phase 1	Recruiting	2024-11	USA
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) NCT07541079 · Early Breast Cancer Drug: Giredestrant	Phase 3	Recruiting	2026-08	USA
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer NCT07567846 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer, Metastatic Prostate Cancer	Phase 1/2	Recruiting	2026-04	UK, USA
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors NCT06619587 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	2024-11	UK, USA
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer NCT05800665 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer, Metastatic Prostate Cancer	Phase 1	Recruiting	2023-05	UK, USA
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) NCT04853251 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration Drugs: Lucentis, Ranibizumab	Phase 4	Recruiting	2021-12	USA
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) NCT07425522 · ClinicalTrials.gov ↗ · Diabetic Macular Edema Drug: Faricimab	Phase 1	Recruiting	2026-04	USA
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy NCT07609719 · ClinicalTrials.gov ↗ · Multiple Sclerosis Drug: Ocrelizumab	Phase 4	Recruiting	2026-09	USA
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251 NCT05626114 · ClinicalTrials.gov ↗ · Geographic Atrophy Drug: OpRegen	Phase 2	Recruiting	2023-03	USA
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib NCT07144111 · ClinicalTrials.gov ↗ · Hepatic Impairment Drug: Inavolisib	Phase 1	Recruiting	2025-08	USA
The Mycophenolate Pregnancy Registry NCT01733082 · ClinicalTrials.gov ↗ · Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases	Observational	Recruiting	2012-11	USA
A Study of RO7890597 in Healthy Adult Volunteers NCT07797478 · ClinicalTrials.gov ↗ · Healthy Volunteers Drugs: Itraconazole, Rabeprazole	Phase 1	Recruiting	2026-08	USA
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Abemaciclib, Giredestrant	Phase 1/2	Recruiting	2025-10	USA, China
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema NCT05224102 · Diabetic Macular Edema Drug: Faricimab	Phase 4	Active, closed	2022-02	USA, India
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer NCT03332797 · Breast Cancer Drugs: Giredestrant, Palbociclib	Phase 1	Active, closed	2017-11	UK, USA
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT03448042 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Tocilizumab, Trastuzumab	Phase 1	Active, closed	2018-06	UK, USA, China
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) NCT06847854 · Diabetic Macular Edema	Phase 1	Active, closed	2022-12	USA
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period NCT06524375 · Chronic Lymphocytic Leukemia Drug: Venetoclax	Phase 2	Active, closed	2024-08	USA
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration NCT05300724 · Age-Related Macular Degeneration	Observational	Active, closed	2022-05	USA
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · ClinicalTrials.gov ↗ · Neoplasm Metastasis Drugs: Atezolizumab, Docetaxel, Paclitaxel	Phase 2	Active, closed	2008-10	UK, USA, China
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis NCT07008378 · Multiple Sclerosis Drugs: Cyclophosphamide, Fludarabine	Phase 1	Active, closed	2025-10	USA
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) NCT05232929 · Spinal Muscular Atrophy Drug: Risdiplam	Phase 4	Active, closed	2022-03	USA
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) NCT05306340 · ClinicalTrials.gov ↗ · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer Drugs: Everolimus, Exemestane, Fulvestrant	Phase 3	Active, closed	2022-08	UK, USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06031441 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors Drug: Atezolizumab	Phase 1	Active, closed	2023-11	UK, USA
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC NCT05968326 · ClinicalTrials.gov ↗ · Adenocarcinoma, Pancreatic Ductal Drugs: Atezolizumab, Autogene cevumeran, MFOLFIRINOX	Phase 2	Active, closed	2023-10	UK, USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation NCT04449874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors Drugs: Atezolizumab, Bevacizumab, Cetuximab	Phase 1	Active, closed	2020-07	UK, USA
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer NCT03006172 · ClinicalTrials.gov ↗ · Breast Cancer, Solid Tumor Drugs: Fulvestrant, Inavolisib, Letrozole	Phase 1	Active, closed	2016-12	UK, USA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies NCT05207670 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma Drugs: Mosunetuzumab, Tocilizumab	Phase 2	Active, closed	2022-02	USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC Drugs: Atezolizumab, Pembrolizumab	Phase 1	Active, closed	2022-10	USA
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. NCT04835805 · ClinicalTrials.gov ↗ · Melanoma Drugs: Belvarafenib, Cobimetinib, Nivolumab	Phase 1	Active, closed	2021-05	USA
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis NCT06096779 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Atezolizumab, Bevacizumab	Phase 2	Active, closed	2024-07	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Genentech in the EU trials register (CTIS)

2 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Genentech as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis 2025-522904-26-00 · CTIS ↗ · Immune System Diseases	Phase 1	Ongoing	Italy, Spain, France + 1 more
A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor 2025-521128-31-00 · CTIS ↗ · Neoplasms Drugs: Abemaciclib, Giredestrant	Phase 1	Ongoing	Spain, Italy, France + 1 more

Drugs in Genentech trials

48 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 8 more in the trial list above.

Conditions in Genentech trials

37 conditions

Breast Cancer3 Diabetic Macular Edema3Advanced Prostate Cancer2Metastatic Prostate Cancer2 Solid Tumor2 Multiple Sclerosis2 Melanoma2 Multiple Myeloma1 Ulcerative Colitis1 Solid Tumors1 Neoplasm Metastasis1Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer1Locally Advanced Solid Tumors1Recurrent Solid Tumors1Metastatic Solid Tumors1Adenocarcinoma, Pancreatic Ductal1Non-Small Cell Lung Cancer1 Colorectal Cancer1 Advanced Solid Tumors1 Non-small Cell Lung Cancer1Atherosclerosis1Non-cystic Fibrosis Bronchiectasis1Chronic Obstructive Pulmonary Disease1Early Breast Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	35	17
Clinical trials in UK	13	5
Clinical trials in China	4	2
Clinical trials in India	2	1
EU register (CTIS)	2	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Genentech trials

How many clinical trials does Genentech sponsor?

Genentech is the lead sponsor of 35 current trials on ClinicalTrials.gov in our USA, UK, China and India registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Genentech trials recruiting?

Yes. 17 of its 35 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Genentech testing?

Its current trials name 48 drugs and biologicals as interventions. The most frequent are Atezolizumab (7), Giredestrant (5), Inavolisib (3), Tocilizumab (3) and Trastuzumab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Genentech clinical trials